Joel Greenblatt Arrowhead Pharmaceuticals, Inc. Transaction History

Gotham Asset Management, LLC

$9.41 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $150,783 - $247,990	5,993 New	5,993 $213,000
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $299,768 - $434,235	-10,706 Reduced 43.53%	13,890 $563,000
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $2,696 - $4,396	-91 Reduced 0.37%	24,596 $813,000
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $343,623 - $625,792	12,365 Added 100.35%	24,687 $869,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $3,526 - $6,227	-89 Reduced 0.72%	12,322 $567,000
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $875 - $1,274	-15 Reduced 0.12%	12,411 $775,000
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $336,750 - $496,589	-5,489 Reduced 30.64%	12,426 $824,000
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $543,455 - $1.06 Million	-12,402 Reduced 40.91%	17,915 $1.38 Million
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $1.05 Million - $1.62 Million	-31,580 Reduced 51.02%	30,317 $1.31 Million
Q2 2020 Aug 13, 2020	SELL	$26.12 - $43.27 $1.19 Million - $1.97 Million	-45,627 Reduced 42.43%	61,897 $2.67 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $637,092 - $1.96 Million	-30,987 Reduced 22.37%	107,524 $3.09 Million
Q4 2019 Feb 14, 2020	SELL	$28.14 - $73.01 $3.65 Million - $9.48 Million	-129,837 Reduced 48.38%	138,511 $8.79 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $4.63 Million - $6.15 Million	176,317 Added 191.58%	268,348 $7.56 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $953,909 - $1.58 Million	54,728 Added 146.71%	92,031 $2.44 Million
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $449,501 - $752,774	37,303 New	37,303 $685,000

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

91.1M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.96B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account